Canbi  Pharma  Tech  Cheklangan

Rochening potentsial "sinfdagi eng yaxshi" kichik molekulali terapiya ijobiy klinik natijalari e'lon qilindi

Jul 22, 2024

2024-yil 18-iyulda Roche vazn yo‘qotish uchun og‘iz orqali qabul qilinadigan kichik molekula CT-996 bo‘yicha 1-bosqich klinik sinovining ijobiy natijalarini e’lon qildi. Ma'lumotlar shuni ko'rsatdiki, 2-toifa diabeti bo'lmagan semiz odamlarda 4 hafta davomida CT{5}} davolashdan keyin o'rtacha vazn yo'qotish 6,1% ni tashkil etdi (p.<0.001), which was clinically significant. The complete research data is expected to be announced at the upcoming medical conference.
Bu safar chop etilgan CT-996-201 sinovi xavfsizlik, tolerantlik, farmakokinetik va farmakodinamikani baholashga qaratilgan koʻp qismli, koʻp kohort, randomizatsiyalangan, ikki marta koʻr, platsebo nazorati ostidagi, bir martalik va koʻp dozani oshirishni oʻrganish boʻyicha I bosqichdir. 2-toifa diabetga chalingan yoki bo'lmagan ortiqcha vaznli yoki semirib ketgan kattalardagi KT-996.
Tahlillar shuni ko'rsatdiki, 4 haftadan so'ng CT-996 guruhidagi bemorlar tana vaznining 7,3% ni, platsebo guruhidagilar esa 1,2% ni yo'qotgan. Ikki guruh orasidagi farq klinik jihatdan ahamiyatli edi (farq qiymati 6,1%, p<0.001). Pharmacokinetic data supports the once daily oral administration regimen of CT-996. In addition, the research results also indicate that the levels of CT-996 in the blood of subjects were not significantly affected during fasting or after standardized high-fat meals. Therefore, the administration of CT-996 may not require consideration of meal time, making it potentially more flexible to administer. Based on the research data, Roche expects CT-996 to not only be used for blood glucose control and weight loss treatment, but also as an oral weight maintenance therapy for patients after receiving injectable weight loss therapy.

goTop